Gsk (GLAXF) Cash from Investing Activities (2009 - 2026)

Gsk's Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$2.0 billion for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 37.17% year-over-year to -$2.0 billion; the TTM figure through Mar 2026 stood at -$3.9 billion (down 52.28% YoY), while the FY2025 annual figure was -$5.6 billion, down 255.27% from the prior year.
• Cash from Investing Activities was -$2.0 billion for Q1 2026 at Gsk, down from -$1.2 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $797.1 million in Q4 2024 to a low of -$4.9 billion in Q4 2022.
• Historically, Cash from Investing Activities has averaged -$1.8 billion across 5 years, with a median of -$1.4 billion in 2025.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities tumbled 7184.1% in 2022, then soared 146.81% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$4.9 billion in 2022, then surged by 64.92% to -$1.7 billion in 2023, then jumped by 146.81% to $797.1 million in 2024, then slumped by 255.7% to -$1.2 billion in 2025, then slumped by 59.26% to -$2.0 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$2.0 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.4 billion (Q1 2025), per Business Quant data.